Delving into the Latest Updates on Nesiritide Recombinant with Synapse

Overview

Basic Info

Drug Type

Recombinant polypeptide

Synonyms

BNP, Brain natriuretic peptide, Brain natriuretic peptide 32

+ [11]

Target

NPRA

Mechanism

NPRA agonists(Natriuretic peptide receptor 1 agonists)

Therapeutic Areas

Cardiovascular DiseasesRespiratory DiseasesUrogenital Diseases

Active Indication-

Inactive Indication

Acute congestive heart failureAcute decompensated heart failureAcute Kidney Injury+ [8]

Originator Organization

Johnson & Johnson

Active Organization-

Inactive Organization

Scios, Inc.

Chengdu Shengnuo Biotechnology Co., Ltd.Scios LLC

+ [2]

Drug Highest PhaseWithdrawn

First Approval Date

US (10 Aug 2001),

Acute decompensated heart failure

Regulation-

Login to view timeline

Gene Sequence

Sequence Code 37334

Source: *****

Accumulating evidence suggests that the natriuretic peptide (NP) hormonal system has important effects on metabolism. However, more information is needed to better understand the effects of NPs on metabolism in humans. Therefore, the investigators propose a study to determine the effects of b-type natriuretic peptide (BNP) on energy and fat metabolism in humans. The investigators' primary hypothesis is that the administration of BNP will increase energy expenditure in humans. The investigators' secondary hypothesis is that BNP administration will promote changes in gene expression in fat tissue suggestive of fat "beiging" in humans. Interventions that safely increase energy expenditure and promote fat "beiging" represent potential strategies for treating metabolic dysfunction due to obesity.

Start Date01 Jul 2018

Sponsor / Collaborator

VA Office of Research and Development

NCT02269072 / WithdrawnNot ApplicableIIT

Testosterone Regulation of the Natriuretic Peptide System

The proposed study is a physiologic investigation of the effects of testosterone on the natriuretic peptide system. The hypotheses of the study are that testosterone administration will decrease natriuretic peptide levels and salt excretion. The entire protocol is 8 weeks in duration.

Start Date01 Feb 2015

Sponsor / Collaborator

The General Hospital Corp.

100 Clinical Results associated with Nesiritide Recombinant

Login to view more data

100 Translational Medicine associated with Nesiritide Recombinant

Login to view more data

100 Patents (Medical) associated with Nesiritide Recombinant

Login to view more data

1,841

Literatures (Medical) associated with Nesiritide Recombinant

31 Dec 2024·ANNALS OF MEDICINE

Accuracy of brain natriuretic peptide and N-terminal brain natriuretic peptide for detecting paediatric pulmonary hypertension: a systematic review and meta-analysis

Review

Author: Yang, Liuping ; Zhou, Ruixi ; Ge, Long ; Qiu, Xia ; Mao, Qian ; Lei, Yupeng

OBJECTIVE:

Pulmonary hypertension (PH) is a life-threatening disease, especially in paediatric population. Symptoms of paediatric PH are non-specific. Accurate detection of paediatric PH is helpful for early treatment and mortality reduction. Therefore, we assessed the overall performance of brain natriuretic peptide (BNP) and N-terminal brain natriuretic peptide (NT-proBNP) for diagnosing PH in paediatric population.

METHODS:

PubMed, Web of Science, Cochrane Library and Embase databases were screened since their respective inceptions until August 2023. A bivariate random model and a hierarchical summary receiver operating characteristic model were used together to evaluate and summarize the overall performance of BNP and NT-proBNP for diagnosing paediatric PH.

RESULTS:

Eighteen studies using BNP/NT-proBNP were assessed, comprising 1127 samples. The pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR) and area under the curve (AUROC) of BNP/NT-proBNP were separately as 0.81, 0.87, 6.33, 0.21, 29.50 and 0.91, suggesting a good diagnostic performance of BNP/NT-proBNP for detecting PH in paediatric population. For BNP, the pooled sensitivity, specificity, PLR, NLR, DOR and AUROC were 0.83, 0.89, 7.76, 0.19, 40.90 and 0.93, indicating the diagnostic accuracy of BNP for paediatric PH patients was good. For NT-proBNP, the pooled sensitivity, specificity, PLR, NLR, DOR and AUROC were 0.81, 0.86, 5.59, 0.22, 24.96 and 0.90, showing that NT-proBNP could provide a good value for detecting paediatric PH.

CONCLUSIONS:

Both BNP and NT-proBNP are good markers for differentiating paediatric PH patients from non-PH individuals.

13 Dec 2024·CHEMISTRY-A EUROPEAN JOURNAL

Recovery of Berry Natural Products Using Pyrene‐Based MOF Solid Phase Extraction

Article

Author: Hurley, Tara ; Remcho, Vincent T. ; Stylianou, Kyriakos C.

Abstract:

This work introduces a novel method of recovering bioactive berry natural products (BNPs) using solid phase extraction with metal‐organic frameworks (MOF‐SPE). Two pyrene‐based MOFs with different structural topologies, Al‐PyrMOF and Zr‐NU‐1000, were evaluated for their ability to capture and desorb BNPs, including ellagic acid, quercetin, gallic acid, and p‐coumaric acid. Time‐dependent BNP uptake via dispersive SPE revealed that NU‐1000 outperformed Al‐PyrMOF in capturing all BNPs. Our findings show NU‐1000 demonstrated a higher and more consistent BNP capture profile, achieving over 90 % capture of all BNPs within 36 h, with only a 9 % variation between the most and least effectively captured BNPs. In contrast, Al‐PyrMOF, displayed a staggered uptake profile, with a significant 53 % difference in capture efficiency between the most and least effectively captured BNP. However, when a BNP mixture was used at a loading concentration of 50 μg/mL, Al‐PyrMOF outperformed NU‐1000, capturing over 70 % of all BNPs. Al‐PyrMOF also exhibited improved BNP recovery, with a minimum of two‐fold greater amount recovered for all BNPs. Further testing with a BNP mixture at a concentration of 15 μg/mL demonstrated that Al‐PyrMOF efficiently concentrated all BNPs, achieving a maximum extraction factor of 2.71 observed for quercetin. These findings highlight the use of Al‐PyrMOF as a MOF‐SPE sorbent for recovering bioactive BNPs.

01 Dec 2024·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Structural characterization of noni (Morinda citrifolia L.) pectin and its inhibitory activity on pancreatic lipase

Article

Author: Gu, Chunhe ; Feng, Zhen ; Liu, Fei ; Wang, Mengrui ; Zhou, Junping ; Chen, Junxia ; Yue, Mingzhe ; Zhang, Chao ; Chang, Ziqing

This study aimed to investigate the physicochemical properties and biological activities of noni pectin (NP) extracted using various solvents, three fractions of noni pectin were obtained using traditional chemical and deep eutectic solvents. NPs are composed of various ratios of galacturonic acid, arabinose, rhamnose, xylose, glucose, and galactose with different yields, molecular weights, esterification degrees (DE), and microstructures. Among the fractions, noni pectin extracted with Betaine-citric acid (BNP) exhibited higher molecular weight, degree for esterification and pancreatic lipase (PL) inhibitory activity than the other fractions. Enzyme kinetic analysis indicated that BNP inhibited PL via a noncompetitive mechanism. BNP significantly altered the secondary structure of PL and quenched PL fluorescence, suggesting a static quenching mechanism. Isothermal titration calorimetry (ITC) further demonstrated that the binding of BNP to PL was spontaneous and driven by enthalpy, primarily mediated by hydrogen bonding and van der Waals forces. Molecular docking simulations also confirmed strong noncovalent interactions (hydrogen bonding and van der Waals forces) between BNP and PL. This study validated the high efficiency of the deep eutectic solvent-extracted noni pectin fraction in pancreatic lipase inhibition.

2

News (Medical) associated with Nesiritide Recombinant

19 Oct 2023

·www.sciencedaily.com

BNP peptide a culprit in eczema

Researchers have pinpointed a particular peptide's role in activating atopic dermatitis, or eczema. The work could lead to more effective treatments for the condition. Researchers from North Carolina State University have pinpointed a particular peptide's role in activating atopic dermatitis, or eczema. The work could lead to more effective treatments for the condition. Atopic dermatitis (AD) is a skin condition characterized by itching, irritated and thickened skin at the site of the irritation. The brain natriuretic peptide (BNP) is a peptide, or short chain of amino acids, that is elevated in patients with AD. "BNP is expressed in sensory neurons, the neurons responsible for conveying sensation to the brain via the spinal cord," says Santosh Mishra, associate professor of molecular biomedical sciences at NC State and corresponding author of the work. "We know from previous work that BNP helps translate the sensation of itch from the skin to the brain. In this work we wanted to see if BNP was involved in activating AD." In a chemically induced mouse model of AD, the researchers saw that mice without BNP did not exhibit the thickened or irritated skin commonly associated with AD, and their itching was reduced compared with control mice who did have BNP. "The results show that BNP likely plays a role in itch activation," Mishra says. "We next looked at BNP's relationship to periostin, to see if we could determine how that activation takes place." Periostin is a protein that can interact with sensory neurons in skin to activate itch response. It is produced in skin cells called keratinocytes and fibroblasts. Keratinocytes in turn, have receptors for BNP, which are called NPR1 receptors. When the BNP receptors are activated, periostin is produced and itch can be turned on. "But the interesting thing here is that the sensory neurons are the activator," Mishra says. The neuron releases BNP, which activates keratinocytes with the NPR1 receptor, which then release the periostin. "This work shows that peripheral neurons, not just central neurons, are playing a role in AD -- it begins in the sensory neurons, and cascades from there," Mishra adds. "It also points to some potential therapeutic strategies, such as blocking BNP's ability to bind to NPR1 receptors in the skin." The research appears as a letter to the editor in the Oct. 11 issue of the Journal of Investigative Dermatology. The work was supported by the National Institutes of Health under grant number 1R56AR077692-01. NC State undergraduate student Junho Yu, former NC State undergraduate student Nidha Williams, and NC State postdoctoral research scholar Joshua Wheeler, also contributed to the work.

26 Apr 2023

·www.prnewswire.com

The Role of Natriuretic Peptides in the Diagnosis and Management of Heart Failure Discussed in New Joint Scientific Statement by the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, and Japanese Heart Failure Society

ROCKVILLE, Md., April 26, 2023 /PRNewswire/ -- The Heart Failure Society of America (HFSA), the Heart Failure Association of the European Society of Cardiology (HFA-ESC) and the Japanese Heart Failure Society (JHFS) announced today a joint scientific statement on Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure. Natriuretic peptides, brain (B-type) natriuretic peptide (BNP) and N-terminal prohormone of brain natriuretic peptide (NT-proBNP), are internationally used as a biomarker for diagnosis and management in adults with heart failure (HF). In addition, natriuretic peptide biomarker data can be important in risk stratification of heart failure prognosis. In addition to biomarker data, implementation of an oral angiotensin receptor neprilysin inhibitor (ARNI) has increased healthcare professionals' awareness of natriuretic peptides as an important therapeutic agent. Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure scientific statement aims to provide a framework and expert recommendations to healthcare professionals on the diagnosis and management of HF and focuses on the following areas: History and basic research: discovery, production, and cardiovascular protection Diagnostic and prognostic biomarkers: acute HF, chronic HF, inclusion/endpoint in clinical trials, and natriuretic peptides-guided therapy Therapeutic use: nesiritide (BNP), carperitide (ANP), and sacubitril (neprilysin inhibitor [combined with an angiotensin receptor blocker]), and Gaps in knowledge and future directions Standardized screening for HF remains challenging because of the heterogeneity of risk factors across different patient populations. Natriuretic peptides are recommended for initial diagnosis of HF as noted in the 2022 ACC/AHA/HFSA Guideline for the Management of HF, 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic HF, and JCS2017/JHF2017 Guideline on diagnosis and treatment of acute and chronic HF. "There are several differences in the statements among HF Societies regarding the use of natriuretic peptides as biomarkers for risk stratification and prevention. The scientific statement provides up-to-date perspectives and guidance that healthcare professionals can use to navigate and provide the best care for their patients with HF," Nancy Albert, PhD, CCNS, CHFN; co-chair and co-author representing HFSA in the Trilateral International Consensus Conference (TICC) said. The joint scientific statement on natriuretic peptides was developed by the TICC, a collaboration of HFSA, JHFS and HFSA-ESC. The TICC 2021 was hosted by the JHFS and was chaired by Hiroyuki Tsutsui, President of the JHFS, with Nancy M. Albert (HFSA) and Andrew Coats (HFA-ESC) serving as co-chairs. The Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure scientific statement will jointly publish on Monday 17 April at 9:00 AM EDT in the Journal of Cardiac Failure, the official journal of the HFSA and the JHFS, and the European Journal of Heart Failure, the official journal of the HFA-ESC. DOI: 10.1016/j.cardfail.2023.02.009 To receive a copy of the manuscript in advance of the embargo, contact [email protected]. About the Heart Failure Society of America The Heart Failure Society of America, Inc. (HFSA) represents the first organized effort by heart failure experts from the Americas to provide a forum for all those interested in heart function, heart failure, and congestive heart failure (CHF) research and patient care. The mission of HFSA is to provide a platform to improve and expand heart failure care through collaboration, education, innovation, research, and advocacy. HFSA members include physicians, scientists, nurses, nurse practitioners, pharmacists, trainees, other healthcare workers and patients. For more information, visit hfsa.org. About the Heart Failure Association of the European Society of Cardiology As the world's largest heart failure association, the Heart Failure Association of the ESC prioritizes patient management and awareness of heart failure as a global health problem. HFA-ESC's mission is to improve quality of life and longevity through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research. Learn more online. About the Japanese Heart Failure Society In response to the increased interest in heart failure, based on the basic studies on its mechanisms and clinical trials, the Japanese Heart Failure Society (JHFS) was established in 1996. The first General and Scientific Meeting of the JHFS was held in October 1997 at the Kyoto International Conference Center. The number of members increased from 900 to approximately 4000 in 2020. The vision of JHFS is to enrich the happy life of the patients and their families through investigating the basic pathophysiology of heart failure, and developing the effective and efficient diagnosis, prevention and treatment strategies. About the Journal of Cardiac Failure The Journal of Cardiac Failure (JCF) publishes the highest quality science in the field of heart failure with a focus on diversity, equity, and inclusion, mentorship, multidisciplinary partnerships, and patient-centeredness. Published papers span original investigator-initiated work to state-of-the-art reviews, guidelines and scientific statements, expert perspectives, early career and trainee spotlight pieces, patient and patient-partner narratives. JCF also emphasizes the power of language and prioritizes innovative approaches to dissemination of published work to reach and impact the broader heart failure community. For more information, visit onlinejcf.com. About the European Journal of Heart Failure The European Journal of Heart Failure (EJHF) is dedicated to the advancement of knowledge in the field of heart failure management. The journal publishes reviews and editorials to improve the understanding, prevention, investigation and treatment of heart failure. Molecular and cellular biology, pathology, physiology, electrophysiology, pharmacology, as well as clinical, social and population sciences all form part of the discipline. Visit EJHF online. Media Contact: Laura Poko: Director of Marketing and Communications, Heart Failure Society of America, 301-798-4493, ext. 226 [email protected] Olivia Seward: Associate Director Communication, European Society of Cardiology, +33 (0)4 89 87 20 10, [email protected] SOURCE Heart Failure Society of America

100 Deals associated with Nesiritide Recombinant

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Nesiritide Recombinant	C01DX19	DB04899

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Acute decompensated heart failure	US	Scios LLC	10 Aug 2001

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Coronary Artery Disease	Phase 3	-	Scios, Inc.	17 Sep 2007
Cardiomyopathies	Phase 3	-	Scios, Inc.	01 Jan 2001
Dyspnea, Paroxysmal	Phase 3	-	Scios, Inc.	01 Jan 2001
Acute congestive heart failure	Phase 3	-	Scios, Inc.	01 Oct 1999
Decompensated chronic heart failure	Phase 3	-	Scios, Inc.	01 Oct 1999
Ventricular Dysfunction, Left	Phase 2	US	Scios, Inc.	01 Mar 2008
Chronic heart failure	Phase 2	US	Scios, Inc.	01 Aug 2003
Acute Kidney Injury	Phase 2	US	Scios, Inc.	01 Mar 2003
Heart Failure, Diastolic	Phase 2	-	Scios, Inc.	01 Dec 2002
Dyspnea	Phase 1	CN	Chengdu Shengnuo Biotechnology Co., Ltd.	22 Sep 2013

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESC2023	Not Applicable	Cardiotoxicity N-terminal pro-brain natriuretic peptide (NT-proBNP)	85	natriuretic peptide	ldhuxjessd(sdrosiirjq) = qrvkgmgvwy loanwhnyja (xdcflltobw )	-	21 May 2023
				natriuretic peptide	ldhuxjessd(sdrosiirjq) = vnxjlgvwon loanwhnyja (xdcflltobw )
ESC2021	Not Applicable	Heart Failure N-terminal pro-B-type natriuretic peptide (NT-proBNP)	444	natriuretic peptide	yikzizqkda(mxbgpemqbt) = myhakycgwu fjplrhdmhl (omnekpqgal ) View more	-	29 Jun 2021
				natriuretic peptide	yikzizqkda(mxbgpemqbt) = hmcuqgyuuh fjplrhdmhl (omnekpqgal ) View more
ASN2019	Not Applicable	-	-	Nesiritide	ypjxrhsuyu(wlfmocorix) = zcpvexgpaq hnivesghjb (klunyfqhny ) View more	-	05 Nov 2019
				No Nesiritide	ypjxrhsuyu(wlfmocorix) = yjbhbxceqa hnivesghjb (klunyfqhny )
ASN2016	Not Applicable	Inflammation AKI \| urine NGAL \| urine IL-18 ... View more	29	Nesiritide	draqdwmacx(pcvygemuby) = drlvfyqssz drgumvxjhv (wxfvyoapjn ) View more	Positive	15 Nov 2016
				Placebo	draqdwmacx(pcvygemuby) = rwefsqiigt drgumvxjhv (wxfvyoapjn ) View more
NCT00405548 (CTgov)	Phase 1/2	Ventricular Dysfunction, Left	41	BNP (nesiritide) (BNP (Nesiritide))	ptmtpcmqxe(crcflexvis) = zrmqgvpray mgnfrigmtp (almxzpczns, hyahehfyjm - jmykxpygsg) View more	-	09 May 2014
				Placebo (Placebo)	ptmtpcmqxe(crcflexvis) = ckydcopfdp mgnfrigmtp (almxzpczns, ndpeyovhcs - cqrgdzwnit) View more
NCT00490724 (CTgov)	Phase 2	Acute decompensated heart failure	67	Nesiritide (2+0.005) (Nesiritide (2+0.005))	ljsvksjotk(kkiaihinek) = cijuserjgt hjmylhhtsh (vkbltegfyn, rtabnkiwbv - bwihrvojoq) View more	-	03 Feb 2014
				Nesritide (2+0.01) (Nesiritide (2+0.01))	ljsvksjotk(kkiaihinek) = vzjhgbynae hjmylhhtsh (vkbltegfyn, innpirvtha - ipzuhxdnxq) View more
NCT00252187 (SubqBNP, CTgov)	Phase 1/2	Heart Failure \| Cardiomyopathies	45	B-type Natriuretic Peptide (BNP) (B-type Natriuretic Peptide (BNP))	rldmtszvzg(fyznfsvsij) = vvgblitlrb iqajilhlhz (jsadkerose, sspwvdphhj - gypyxtaqyu) View more	-	20 Dec 2012
				Placebo (Placebo)	rldmtszvzg(fyznfsvsij) = mqdnvjlseg iqajilhlhz (jsadkerose, jwcoiumfsv - smnquvewav) View more
NCT00475852 (ASCEND-HF, CTgov)	Phase 3	Acute decompensated heart failure	7,141	Nesiritide (Nesiritide)	ykmmphiecf(javclxefdw) = kndvohfuvv ofpxpcbicr (dgerkudcwa, poencufymb - tykuxdtqew) View more	-	10 May 2012
				placebo (Placebo)	ykmmphiecf(javclxefdw) = zuumkqhpjb ofpxpcbicr (dgerkudcwa, gmtvjrcoqy - jrbgiaptlk) View more
ASN2011	Not Applicable	Acute Kidney Injury natriuretic peptide \| loop diuretics	-	Natriuretic peptide (NP)	utmpnposko(rkynzweokh) = iduniljuwn voyadoymje (fxfuvhwcgg, -0.82 to -0.06) View more	Positive	08 Nov 2011
NCT00338455 (CTgov)	Phase 2	Heart Failure	16	Milrinone+Dobutamine+Natrecor (Nesiritide) (Natrecor (Nesiritide)+Standard Care+Dobutamine or Milrinone)	xywzbrrjku(bewrofbfhr) = wqhtesucab tbiuopwkbx (vletkudbme, hfmblppjgp - rwaahmiqde) View more	-	05 Dec 2008
				Placebo+Milrinone+Dobutamine (Placebo + Standard Care + Dobutamine or Milrinone)	xywzbrrjku(bewrofbfhr) = jfnpjbvdgw tbiuopwkbx (vletkudbme, yzevacteys - jrolfcupdd) View more